Advertisement

Adjuvant Therapies and Markers of Post-Surgical Minimal Residual Disease I

Markers and General Problems of Cancer Adjuvant Therapies

  • Gianni Bonadonna
  • Georges Mathé
  • Sydney E. Salmon

Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 67)

Table of contents

  1. Front Matter
    Pages I-XVIII
  2. Introduction

    1. P. Denoix, G. Mathé
      Pages 1-2
  3. Incidence, Kinetics and Markers of Post-Surgical Minimal Residual Disease

    1. Front Matter
      Pages 3-3
    2. S. E. Salmon
      Pages 5-15
    3. X. Y. Bertagna, W. E. Nicholson, K. Tanaka, C. D. Mount, G. D. Sorenson, O. S. Pettengill et al.
      Pages 16-25
    4. R. E. Myers, D. J. A. Sutherland, J. W. Meakin, D. G. Malkin, J. A. Kellen, A. Malkin
      Pages 26-32
    5. J. C. Hendrick, P. F. Zangerle, P. Franchimont
      Pages 39-44
    6. A. G. Foti, J. F. Cooper, H. Herschman
      Pages 45-49
    7. A. M. Roch, G. A. Quash, J. P. Ripoll, S. Saez
      Pages 56-62
    8. C. Rosenfeld, C. Jasmin, G. Mathé, M. Inbar
      Pages 63-77
    9. R. Maurus, J. Otten
      Pages 78-84
    10. R. W. Baldwin, K. Höffken, R. A. Robins
      Pages 85-87
  4. Adjuvant Therapies of Post-Surgical Minimal Residual Disease

    1. Front Matter
      Pages 105-105
    2. Rational and Experimental Basis of Post-Surgical Residual Therapies

      1. L. M. van Putten, J. de Ruiter, C. J. H. van de Velde, J. H. Mulder, A. F. C. Gerritsen
        Pages 119-125
      2. Y. Rustum, Y. C. Cheng, Z. Pavelic, P. Creaven, E. Mihich
        Pages 126-131
      3. G. Mathé, L. Olsson, I. Florentin, N. Kiger, S. Orbach-Arbouys, J. I. Schulz
        Pages 132-150
  5. Back Matter
    Pages 151-152

About this book

Introduction

P. Denoix and G. Mathe Approximately 70% of cancer patients relapse after surgery before the 5th year and, in most cases, for example in breast carcinoma, they relapse still later up to the 20th year. For some considerable time, the strategy of cancer treatment has been limited to the sophistication of surgery-radiotherapy combinations that maximally decreased the incidence of local and regional relapses in sites that were within their reach. Today, the practice of clinical oncology is unthinkable without the active participation of the medical oncologist. He is the "third man" of the clinical oncology team, and he has recently focused attention on the fact that most relapses arise from distant metastases due to the proliferation of cells seeded there after having left the primary tumor site at the time of operation and, hence, are inaccessible to any form oflocal and/or regional treatment. On this evidence, medical oncologists have proposed the application of medical treatments for disseminated minimal residual disease (MRD). They have two available means: chemother­ apy and immunotherapy. Medical oncologists in general can be divided into three groups: chemotherapists, immunotherapists, and chemoimmunotherapists. The pure chemotherapists, who had already cured some malignant neoplasias such as Hodgkin's disease, acute lymphoid leukemia, placental choriocarcinoma, and Wilms' tumor, thought they might have the means of attacking the residual disease of common cancers.

Keywords

Immunotherapie Krebs cancer treatment carcinoma immunotherapy leukemia lymphocytes marker metastasis microviscosity of lymphocytes prostatic acid phosphatimmune radioimmunoassay radiotherapy surgery tumor

Editors and affiliations

  • Gianni Bonadonna
    • 1
  • Georges Mathé
    • 2
  • Sydney E. Salmon
    • 3
  1. 1.Istituto Nazionale dei TumoriMilanoItaly
  2. 2.Institut de Cancérologie et d’ImmunogénétiqueHôpital Paul-BrousseVillejuifFrance
  3. 3.University of Arizona Cancer CenterTucsonUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-642-81320-7
  • Copyright Information Springer-Verlag Berlin Heidelberg 1979
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-81322-1
  • Online ISBN 978-3-642-81320-7
  • Series Print ISSN 0080-0015
  • Buy this book on publisher's site
Industry Sectors
Pharma
Health & Hospitals
Biotechnology
Oncology & Hematology